• 1
    International Union Against Cancer. TNM classification of malignant tumors. 4th ed. Berlin: Springer-Verlag; 1987.
  • 2
    Denoix PF. TNM classification. Bull Inst Natl Hyg (Paris) 1944;5:5259.
  • 3
    BeahrsOH, HensonDE, HutterRVP, et al., editors. Manual for staging of cancer. 4th ed. American Joint Committee on Cancer. Philadelphia: Lippincott; 1992.
  • 4
    Montie JE. Staging of prostate cancer. Cancer 1994;74:13.
  • 5
    Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110114.
  • 6
    Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528537.
  • 7
    Kirby RS. Pre-treatment staging of prostate cancer: recent advances and future prospects. Prostate Cancer Prostatic Dis 1997;1:2.
  • 8
    Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:18501857.
  • 9
    Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:18371842.
  • 10
    Scardino PT, Shinohara K, Wheeler TM, Carter SS. Staging of prostate cancer: value of ultrasonography. Urol Clin North Am 1989;16:713734.
  • 11
    Montie JE. Staging of prostate cancer: current TNM classification and future prospects for prognostic factors. Cancer 1995;75:1814.
  • 12
    Pinover WH, Hanlon A, Lee WR, Kaplan EJ, Hanks GE. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. Cancer 1996;77:13341341.
  • 13
    Cupp MR, Oesterling JE. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer. Mayo Clin Proc 1993;68:297306.
  • 14
    Ohori M, Egawa S, Shinohara K, Wheeler TM, Scardino PT. Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. Br J Urol 1994;74:7279.
  • 15
    Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography: weaknesses and new perspectives. Urology 1992;40:346350.
  • 16
    Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, Hamper U, Walsh PC, McNeil BJ. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trail. N Engl J Med 1990;323:621626.
  • 17
    Chelsky MJ, Schnall MD, Seidmon EJ, Pollack HM. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol 1993;150:391395.
  • 18
    Scheibler ML, Schnall MD, Pollack HM, Lenkinski RE, Tomaszewski JE, Wein AJ, Whittington R, Rauschning W, Kressel HY. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 1993;189:339352.
  • 19
    Kier R, Wain S, Troiano R. Fast spin-echo MR images of the pelvis obtained with a phased-array coil: value in localizing and staging prostatic carcinoma. Am J Roentgenol 1993;161:601606.
  • 20
    Daniels GF, McNeal JE, Stamey TA. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer. J Urol 1992;147:870874.
  • 21
    Huland H, Hammerer P, Henke RP, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J Urol 1996;155:13441347.
  • 22
    Huland H, Hubner D, Henke RP. Systematic biopsies and digital rectal examination to identify the nerve-sparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2, N0 prostatic carcinoma. Urology 1994;44:211214.
  • 23
    Terris MK, McNeal JE, Freiha FS, Stamey TA. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol 1993;149:10351039.
  • 24
    Stone NN, Stock RG, Unger P. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995;154:13921396.
  • 25
    Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:10111017.
  • 26
    Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747752.
  • 27
    Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:5760.
  • 28
    Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy: influence of clinical stage and tumor grade. Urology 1993;41:207216.
  • 29
    Hanks GE, Krall JM, Pilepich MV, Asbell SO, Perez CA, Rubin P, Sause WT, Doggett RL. Comparison of Pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification. Int J Radiat Oncol Biol Phys 1992;23:293298.
  • 30
    Schuessler WW, Pharand D, Vancaillie TG. Laprascopic standard pelvic node dissection for carcinoma of the prostate: is it accurate? J Urol 1993;150:898901.
  • 31
    Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 1994;151:13101314.
  • 32
    Fournier GR, Narayan P. Re-evaluation of the Need for pelvic lymphadenectomy in low grade prostate cancer. Br J Urol 1993;72:484488.
  • 33
    Huncharek M, Muscat J. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest 1995;13:3135.
  • 34
    Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 1993;20:705711.
  • 35
    Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 1994;17:432436.
  • 36
    Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B. Preliminary imaging results using In-111 labeled CYT-356 (ProstascintTM) in the detection of recurrent prostate cancer. Clin Nucl Med 1996;21:759767.
  • 37
    FlemingID, CooperJS, HensonDE, et al., editors. AJCC cancer staging manual. 5th ed. American Joint Committee on Cancer. Philadelphia: Lippincott-Raven; 1997.
  • 38
    Roach M. The role of PSA in the radiotherapy of prostate cancer. Oncology (Hungtingt) 1996;10:11431161.
  • 39
    Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt MC, McLeod DG, Srivastava S, Moul JW. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 1997;79:952962.